Illumina, Inc. (ILMN) falls 11.7% after Q3 revenue miss
Illumina, Inc. (ILMN) falls sharply after reporting third-quarter results that beat adjusted profit estimates but missed on revenue. The company also raised full-year guidance, yet investors focused on the sales shortfall and the stock’s extended-hours drop.
Illumina, Inc. (ILMN) falls 11.7% in after-hours trading after its third-quarter report showed a revenue miss despite an adjusted EPS beat and higher full-year guidance. The selloff suggests investors are prioritizing sales quality and growth momentum over the profit beat, which could keep pressure on the stock until regular-session trading confirms the move.
Illumina, Inc. (ILMN) falls sharply in after-hours trading after reporting third-quarter 2026 results, with the stock printing at $256 versus a $290.06 regular-session close. The decline reflects a mixed earnings picture: Illumina beat adjusted EPS estimates and raised full-year guidance, but reported revenue of $1.13 billion below analyst expectations. This is an extended-hours move, so regular-session trading will confirm whether the drop holds.
Key Takeaways
ILMN traded at $256 in after-hours trading, down 11.74% from the prior close of $290.06.
The primary catalyst was Illumina’s Q3 2026 report, which showed adjusted EPS of $1.44 versus a $1.36 analyst estimate.
Revenue reached $1.13 billion, up 4.2% year over year, but fell short of Wall Street expectations.
Illumina raised full-year revenue and earnings guidance, including a $4.65 billion revenue midpoint that sits 0.6% above consensus.
The selloff puts valuation and revenue quality under the microscope, even though the company still holds a strong sequencing platform and recurring consumables model.
The clearest catalyst is Illumina’s third-quarter earnings report, published after the October 29 close. The timing matches the sharp after-hours move, and no separate company-specific event in the prior 24 to 48 hours offers a stronger explanation.
The report delivered a split verdict. Adjusted EPS came in at $1.44, above the $1.36 average estimate from five analysts surveyed by Zacks Investment Research. That result also matches coverage citing an $0.08 EPS beat. GAAP net income reached $220 million, while GAAP EPS was $1.43.
Revenue created the problem. Illumina posted $1.13 billion, up 4.2% from the same quarter a year earlier, but news coverage reported that sales missed analyst estimates. Investors often tolerate a revenue miss when profit growth is strong. However, a revenue miss can still pressure a growth-oriented stock when the shares carry a demanding valuation.
Broader earnings pressure in technology also added noise, with Amazon and Intel among other reported overnight losers. Still, the same-day Q3 report remains the dominant ILMN catalyst. A Stephens downgrade to Equal Weight on October 23 and a Canaccord Genuity target increase to $300 on October 19 were earlier events, not fresh explanations for this immediate move.
Illumina Financial Results Show Profit Strength but Revenue Friction
The underlying numbers explain why the stock reaction looks harsher than the headline earnings beat. Illumina reported $1.17 billion of revenue excluding tariff refunds. That figure increased 4.7% after excluding currency, acquisitions, and Greater China effects.
This adjusted view shows continued growth outside the company’s most difficult areas. Yet the gap between $1.13 billion of reported revenue and $1.17 billion excluding tariff refunds highlights why investors focus on revenue quality. Greater China effects, tariffs, currency, and acquisitions complicate the headline comparison.
Illumina also reported a 27.0% GAAP operating margin. More importantly, the company raised full-year revenue and earnings guidance based on continued momentum. The full-year revenue midpoint of $4.65 billion stands 0.6% above analyst consensus.
That guidance increase gives investors a constructive forward signal. At the same time, the market’s response shows that guidance alone did not offset concern about quarterly sales. In plain English, management improved the destination, but investors disliked part of the road taken to get there.
ILMN Valuation and Competitive Position After the Drop
Illumina’s financial profile gives the selloff additional importance. The company has a $43.80 billion market capitalization and a P/E of 53.8787. That multiple leaves less room for revenue execution problems than a lower-valued stock would have.
The shares have traded between $106.12 and $309.35 over the past 52 weeks. The $256 after-hours price sits near the $252.73 analyst consensus target and the $260 median target. Those figures do not determine fair value, but they show that the post-earnings price is close to the central range of published targets.
The business still has meaningful competitive advantages. Illumina sells sequencing and microarray instruments, consumables, software, and services. Its installed base supports recurring demand for reagents, flow cells, and library preparation products.
The company also serves genomic research centers, hospitals, pharmaceutical companies, biotechnology firms, and diagnostic laboratories. That customer reach supports Illumina’s long-term position. However, competition, pricing pressure, China-related regulatory risk, and execution risk remain material constraints.
The practical takeaway is to separate the earnings signal from the trading reaction. The earnings signal is mixed, not uniformly negative. Illumina beat adjusted EPS estimates, delivered a 27.0% GAAP operating margin, and raised full-year guidance. The negative signal is the $1.13 billion revenue result and the market’s sharp response to that shortfall.
A disciplined investor can use three reference points. First, compare the $1.13 billion reported revenue with the $1.17 billion figure excluding tariff refunds. Second, weigh the $4.65 billion guidance midpoint against the quarterly sales miss. Third, judge whether the $256 after-hours price makes the 53.8787 P/E more attractive relative to the company’s growth rate.
The business case remains tied to clinical sequencing, consumables growth, and recovery in research demand. Recent company commentary identified clinical demand as the main growth driver while research activity continued recovering. Therefore, the raised guidance supports the long-term story, but the revenue miss shows that execution still matters greatly.
Investors should avoid treating one after-hours print as a complete verdict on Illumina. Regular-session volume and price action will provide a better test of whether the market views the report as a temporary revenue stumble or a deeper growth concern.
Illumina falls because Q3 revenue missed expectations, despite a $1.44 adjusted EPS beat and higher full-year guidance. The company retains a powerful sequencing platform, but its valuation demands reliable revenue execution. For investors, the central issue is whether guidance strength can outweigh near-term concerns about sales quality, China exposure, and research-market recovery.
ILMN is down because Illumina’s Q3 revenue came in below analyst expectations, even though adjusted EPS beat estimates and the company raised full-year guidance. Investors appear to be focusing on the sales miss and the quality of growth rather than the profit beat.
+Should I buy ILMN stock now?
The report is mixed, so this is not a clear buy-the-dip setup based on the earnings reaction alone. Investors may want to wait for regular-session confirmation and more clarity on whether the revenue miss was a one-quarter issue or a broader growth concern.
+Did Illumina beat earnings expectations?
Yes. Illumina reported adjusted EPS of $1.44, above the $1.36 analyst estimate. However, the stock still fell because revenue missed expectations.
+What does the guidance raise mean for ILMN investors?
The higher guidance is a constructive sign because management sees stronger full-year performance ahead. Even so, the market is signaling that investors want to see better quarterly revenue execution before rewarding the stock.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on ILMN?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.